Bioventus News

Bioventus Analyst Ratings

BenzingaMar 13 10:45 ET

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)

TipRanksMar 13 07:11 ET

Analysts Offer Insights on Healthcare Companies: Clene (CLNN), REPRO-MED Systems (KRMD) and Bioventus (BVS)

TipRanksMar 11 08:40 ET

Analysts Are Bullish on Top Healthcare Stocks: Bioventus (BVS), Palatin Technologies (PTN)

TipRanksDec 20, 2023 08:40 ET

Canaccord Genuity Upgrades Bioventus to Buy, Raises Price Target to $7

BenzingaDec 7, 2023 05:31 ET

Bioventus Analyst Ratings

BenzingaDec 7, 2023 05:29 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Augmedix (AUGX), Biodesix (BDSX) and Bioventus (BVS)

TipRanksNov 8, 2023 07:50 ET

Analysts Offer Insights on Healthcare Companies: Aadi Bioscience (AADI) and Bioventus (BVS)

TipRanksMay 17, 2023 09:01 ET

Bioventus (BVS) Gets a Buy From Craig-Hallum

TipRanksMay 8, 2023 09:15 ET

Canaccord Genuity Keeps Their Hold Rating on Bioventus (BVS)

TipRanksApr 10, 2023 09:06 ET

Craig-Hallum Adjusts Price Target on Bioventus to $5 From $10, Maintains Hold Rating

MT NewswiresApr 3, 2023 10:12 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL) and Bioventus (BVS)

TipRanksApr 3, 2023 08:41 ET

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), DENTSPLY SIRONA (XRAY) and Bioventus (BVS)

TipRanksMar 1, 2023 06:08 ET

Analysts Offer Insights on Healthcare Companies: Apollo Endosurgery (APEN) and Bioventus (BVS)

TipRanksNov 30, 2022 12:45 ET

Goldman Sachs Cuts Price Target on Bioventus to $2.50 From $13, Maintains Neutral Rating

MT NewswiresNov 30, 2022 09:17 ET

What 4 Analyst Ratings Have To Say About Bioventus

Benzinga Real-time NewsNov 30, 2022 09:07 ET

Bioventus Analyst Ratings

Benzinga Analyst RatingsNov 30, 2022 08:32 ET

Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5

Benzinga Real-time NewsNov 30, 2022 08:32 ET

Bioventus Analyst Ratings

Benzinga Analyst RatingsNov 22, 2022 07:29 ET

Morgan Stanley Adjusts Price Target on Bioventus to $5 From $11, Maintains Overweight Rating

MT NewswiresNov 10, 2022 09:33 ET